| Description | DRC3 Human Pre-designed siRNA Set A contains three designed siRNAs for DRC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DRC3 siRNA-1: 5 nmol (HPLC) DRC3 siRNA-2: 5 nmol (HPLC) DRC3 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 DRC3 Human Pre-designed siRNA Set A contains three designed siRNAs for DRC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DRC3 siRNA-1: 5 nmol (HPLC) DRC3 siRNA-2: 5 nmol (HPLC) DRC3 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Inquire | Purity> 96% by SDS-PAGE and HPLC analyses.FunctionHas weak activities on human monocytes and acts via receptors that also recognize MIP-1 alpha. It induced intracellular Ca(2+) changes and enzyme release, but no chemotaxis, at concentrations of 100-1,000 nM, and was inactive on T-lymphocytes, Purity> 96% by SDS-PAGE and HPLC analyses.FunctionHas weak activities on human monocytes and acts via receptors that also recognize MIP-1 alpha. It induced intracellular Ca(2+) changes and enzyme release, but no chemotaxis, at concentrations of 100-1,000 nM, and was inactive on T-lymphocytes, neutrophils, and eosinophil leukocytes. Enhances the proliferation of CD34 myeloid progenitor cells. The processed form HCC-1(9-74) is a chemotactic factor that attracts monocytes eosinophils, and T-cells and is a ligand for CCR1, CCR3 and CCR5.Post-translationalThe N-terminal processed forms HCC-1(3-74), HCC-1(4-74) and HCC-1(9-74) are produced in small amounts by proteolytic cleavage after secretion in blood. HCC-1(1-74), but not HCC-1(3-74) and HCC-1(4-74), is partially O-glycosylated; the O-linked glycan consists of one Gal-GalNAc disaccharide, further modified by two N-acetylneuraminic acids... Read More | Inquire |